Cost-effectiveness of HIV screening in patients older than 55 years of age

Annals of Internal Medicine

Volumn 148, Issue 12, 2008, Pages 889-903

  Sanders, Gillian D ^a   Bayoumi, Ahmed M ^b   Holodniy, Mark ^c   Owens, Douglas K ^d  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SENSITIVITY ANALYSIS; SEXUALITY; VIRUS IDENTIFICATION; AGE; COST BENEFIT ANALYSIS; COUNSELING; DISEASE COURSE; DISEASE TRANSMISSION; ECONOMICS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; MASS SCREENING; MIDDLE AGED; PROBABILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEXUAL BEHAVIOR;

AGE FACTORS; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; COUNSELING; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEXUAL BEHAVIOR;

EID: 45549092356     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-148-12-200806170-00002     Document Type: Article

References (162)

1. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17; quiz CE1-4. [PMID: 16988643]
2. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-85. [PMID: 15703422]
3. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145:797-806. [PMID: 17146064]
4. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-95. [PMID: 15703423]
5. Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? Ann Intern Med. 2006;145:459-62. [PMID: 16983134]
6. Centers for Disease Control and Prevention (CDC). HIV/AIDS surveillance report, 2005, vol 17. Atlanta: U.S. Department of Health and Human Services; 2007.
7. Espinoza L, Hall HI, Hardnett F, Selik RM, Ling Q, Lee LM. Characteristics of persons with heterosexually acquired HIV infection, United States 1999-2004. Am J Public Health. 2007;97:144-9. [PMID: 17138918]
8. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684-91. [PMID: 17420427]
9. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-8. [PMID: 8849754]
10. Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, et al. Veterans Aging Cohort 5-Site Study Project Team. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004;18 Suppl 1:S49-59. [PMID: 15075498]
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38. [PMID: 8246705]
12. Lemp GF, Hirozawa AM, Givertz D, Nieri GN, Anderson L, Lindegren ML, et al. Seroprevalence of HIV and risk behaviors among young homosexual and bisexual men. The San Francisco/Berkeley Young Men's Survey. JAMA. 1994;272:449-54. [PMID: 8040980]
13. Sinclair M, Bor R, Evans A, Glass D, Levitt D, Johnson MA. The sociodemographic profile, risk categories and prevalence of HIV infection among people attending a London same-day testing clinic, 2000-2001. Int J STD AIDS. 2004;15:33-7. [PMID: 14769169]
14. Centers for Disease Control and Prevention (CDC). Advancing HIV prevention: new strategies for a changing epidemic - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329-32. [PMID: 12733863]
15. Bindman AB, Osmond D, Hecht FM, Lehman JS, Vranizan K, Keane D, et al. Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group. JAMA. 1998;280:1416-20. [PMID: 9801001]
16. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339:1897-904. [PMID: 9862946]
17. Zingmond DS, Kilbourne AM, Justice AC, Wenger NS, Rodriguez-Barradas M, Rabeneck L, et al. Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr. 2003;33 Suppl 2:S84-92. [PMID: 12853857]
18. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science. 1995;270:1372-5. [PMID: 7481828]
19. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health. 2001;91:1060-8. [PMID: 11441732]
20. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2004:1-198. [PMID: 15227812]
21. Centers for Disease Control and Prevention (CDC). HIV/AIDS surveillance report 2002, vol 14. Accessed at www.cdc.gov/hiv/topics/ surveillance/resources/reports/2002report/pdf/2002SurveillanceReport.pdf on 2 May 2008.
22. Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118:890-8. [PMID: 16084183]
23. Turner BJ, Hecht FM, Ismail RB. CD4+ T-lymphocyte measures in the treatment of individuals infected with human immunodeficiency virus type 1. A review for clinical practitioners. Arch Intern Med. 1994;154:1561-73. [PMID: 7913314]
24. Harris RL, Boisaubin EV, Salyer PD, Semands DF. Evaluation of a hospital admission HIV antibody voluntary screening program. Infect Control Hosp Epidemiol. 1990;11:628-34. [PMID: 2125612]
25. Irwin K, Olivo N, Schable CA, Weber JT, Janssen R, Ernst J. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. CDC-Bronx-Lebanon HIV Serosurvey Team. Ann Intern Med. 1996;125:471-5. [PMID: 8779459]
26. Kelen GD, Shahan JB, Quinn TC. Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing. Ann Emerg Med. 1999;33:147-55. [PMID: 9922409]
27. Owens DK, Nease RF Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156:394-404. [PMID: 8607724]
28. Schwartz JS, Kinosian BP, Pierskalla WP, Lee H. Strategies for screening blood for human immunodeficiency virus antibody. Use of a decision support system. JAMA. 1990;264:1704-10. [PMID: 2204738]
29. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med. 2000;109:568-76. [PMID: 11063959]
30. Centers for Disease Control (CDC). Update: serologic testing for antibody to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1988;36:833-40, 845. [PMID: 3121999]
31. MacDonald KL, Jackson JB, Bowman RJ, Polesky HF, Rhame FS, Balfour HH Jr, et al. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med. 1989;110:617-21. [PMID: 2648922]
32. Kelen GD, Hexter DA, Hansen KN, Humes R, Vigilance PN, Baskerville M, et al. Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program. Ann Emerg Med. 1996;27:687-92. [PMID: 8644953]
33. Kassler WJ, Dillon BA, Haley C, Jones WK, Goldman A. On-site, rapid HIV testing with same-day results and counseling. AIDS. 1997;11:1045-51. [PMID: 9223740]
34. Holman S, Sorin MD, Crossette J, LaChance-McCullough ML. A state program for postpartum HIV counseling and testing. Public Health Rep. 1994;109:521-9. [PMID: 8041852]
35. Centers for Disease Control and Prevention (CDC). HIV counseling and testing in publicly funded sites: Annual report, 1997 and 1998. Atlanta: Centers for Disease Control and Prevention; 2001. Accessed at www.cdc.gov/hiv/topics/testing/resources/reports/pdf/cts98.pdf on 2 May 2008.
36. Erickson B, Wasserheit JN, Rompalo AM, Brathwaite W, Glasser D, Hook EW 3rd. Routine voluntary HIV screening in STD clinic clients: characterization of infected clients. Sex Transm Dis. 1990;17:194-9. [PMID: 2264008]
37. Centers for Disease Control and Prevention (CDC). Voluntary HIV testing as part of routine medical care - Massachusetts, 2002. MMWR Morb Mortal Wkly Rep. 2004;53:523-6. [PMID: 15215739]
38. Centers for Disease Control and Prevention (CDC). Routinely recommended HIV testing at an urban urgent-care clinic - Atlanta, Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:538-41. [PMID: 11446572]
39. Hightow LB, Miller WC, Leone PA, Wohl D, Smurzynski M, Kaplan AH. Failure to return for HIV posttest counseling in an STD clinic population. AIDS Educ Prev. 2003;15:282-90. [PMID: 12866839]
40. HITS-2000 Investigators. Failure to return for HIV test results among persons at high risk for HIV infection: results from a multistate interview project. J Acquir Immune Defic Syndr. 2004;35:511-8. [PMID: 15021316]
41. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services; 2008. Accessed at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf on 29 January 2008.
42. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-65. [PMID: 15249575]
43. Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee. Lancet. 1999;353:2061-4. [PMID: 10376634]
44. Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med. 2000;160:1134-40. [PMID: 10789606]
45. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-7. [PMID: 9833857]
46. Rhone SA, Hogg RS, Yip B, Sherlock C, Conway B, Schechter MT, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS. 1998;12:619-24. [PMID: 9583602]
47. Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, et al. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS. 1999;13:F53-8. [PMID: 10357371]
48. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-33. [PMID: 9287227]
49. Maher K, Klimas N, Fletcher MA, Cohen V, Maggio CM, Triplett J, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center. J Acquir Immune Defic Syndr. 1999;22:358-63. [PMID: 10634197]
50. Drusano GL, Stein DS. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob Agents Chemother. 1998;42:358-61. [PMID: 9527786]
51. Keita-Perse O, Roger PM, Pradier C, Pugliese P, Cottalorda J, Dellamonica P. Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count? AIDS. 1998;12:F175-9. [PMID: 9814859]
52. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54. [PMID: 9182471]
53. Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses. 1999;15:499-508. [PMID: 10221527]
54. Centers for Disease Control and Prevention (CDC). Diagnosis and reporting of HIV and AIDS in states with integrated HIV and AIDS surveillance - United States, January 1994-June 1997. MMWR Morb Mortal Wkly Rep. 1998;47:309-14. [PMID: 9579968]
55. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-24. [PMID: 9764780]
56. Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, et al. Aproco Study Group. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002;16:21-9. [PMID: 11741159]
57. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-43. [PMID: 10397555]
58. Report of the NIH Panel to Define Principles of Therapy of HIV Infection. MMWR Morb Mortal Wkly Rep. 1998;47:1-41.
59. de Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS. 1997;11:1799-806. [PMID: 9412697]
60. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-9. [PMID: 7887550]
61. Ioannidis JP, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS. 1996;10:255-62. [PMID: 8882664]
62. Keet IP, Janssen M, Veugelers PJ, Miedema F, Klein MR, Goudsmit J, et al. Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts -200 for <5 years. J Infect Dis. 1997;176:665-71. [PMID: 9291313]
63. O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:155-61. [PMID: 9637580]
64. Spijkerman IJ, Prins M, Goudsmit J, Veugelers PJ, Coutinho RA, Miedema F, et al. Early and late HIV-1 RNA level and its association with other markers and disease progression in long-term AIDS-free homosexual men. AIDS. 1997;11:1383-8. [PMID: 9302449]
65. Henrard DR, Phillips JF, Muenz LR, Blattner WA, Wiesner D, Eyster ME, et al. Natural history of HIV-1 cell-free viremia. JAMA. 1995;274:554-8. [PMID: 7629984]
66. Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, et al. UK Collaborative HIV Cohort (CHIC) Study. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370:1923-8. [PMID: 18068516]
67. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-7. [PMID: 10419445]
68. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naīve Patients. AIDS. 2000;14:499-507. [PMID: 10780712]
69. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;23:236-45. [PMID: 10839659]
70. Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A, et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med. 1999;159:1771-6. [PMID: 10448781]
71. Welch K, Morse A, Clark R, Ogbuokiri T. Factors associated with incomplete virological response to highly active antiretroviral therapy [Letter]. Clin Infect Dis. 2000;30:407-8. [PMID: 10671360]
72. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med. 1997;126:939-45. [PMID: 9182470]
73. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40-7. [PMID: 9419168]
74. Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet. 1997;350:983-90. [PMID: 9329513]
75. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996;174:704-12. [PMID: 8843206]
76. Galetto-Lacour A, Yerly S, Perneger TV, Baumberger C, Hirschel B, Perrin L. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. J Infect Dis. 1996; 173:1388-93. [PMID: 8648210]
77. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126:929-38. [PMID: 9182469]
78. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996;335:1091-8. [PMID: 8813039]
79. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-70. [PMID: 8638160]
80. Montaner JS, DeMasi R, Hill AM. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS. 1998;12:F23-8. [PMID: 9543436]
81. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-10. [PMID: 8656501]
82. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-31. [PMID: 8552144]
83. Pedersen C, Katzenstein T, Nielsen C, Lundgren JD, Gerstoft J. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:93-9. [PMID: 9358103]
84. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA. 1998;279:35-40. [PMID: 9424041]
85. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996;174:696-703. [PMID: 8843205]
86. Yerly S, Perneger TV, Hirschel B, Dubuis O, Matter L, Malinverni R, et al. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. The Swiss HIV Cohort Study. Arch Intern Med. 1998;158:247-52. [PMID: 9472204]
87. Chêne G, Binquet C, Moreau JF, Neau D, Pellegrin I, Malvy D, et al. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidé miologie Clinique du SIDA en Aquitaine. AIDS. 1998;12:2313-20. [PMID: 9863874]
88. Loveday C, Hill A. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count [Letter]. Lancet. 1995;345:790-1. [PMID: 7891499]
89. Goetz MB, Boscardin WJ, Wiley D, Alkasspooles S. Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS. 2001;15:1576-9. [PMID: 11504992]
90. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18:2029-38. [PMID: 15577624]
91. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57:4-7. [PMID: 16284223]
92. Grimes RM, Otiniano ME, Rodriguez-Barradas MC, Lai D. Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis. 2002;34:1530-3. [PMID: 12015701]
93. Knobel H, Guelar A, Valldecillo G, Carmona A, González A, López-Colomés JL, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up [Letter]. AIDS. 2001;15:1591-3. [PMID: 11505000]
94. Manfredi R. HIV infection and advanced age emerging epidemiological, clinical, and management issues. Ageing Res Rev. 2004;3:31-54. [PMID: 15164725]
95. Nogueras M, Navarro G, Antón E, Sala M, Cervantes M, Amengual M, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis. 2006;6:159. [PMID: 17087819]
96. Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7:549-57. [PMID: 17105515]
97. Tumbarello M, Rabagliati R, de Gaetano Donati K, Bertagnolio S, Montuori E, Tamburrini E, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis. 2004;4:46. [PMID: 15530169]
98. Viard JP, Mocroft A, Chiesi A, Kirk O, Røge B, Panos G, et al. EuroSIDA Study Group. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290-4. [PMID: 11262215]
99. Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut JA, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998;339:1269-76. [PMID: 9791142]
100. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998;339:1261-8. [PMID: 9791141]
101. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280:35-41. [PMID: 9660361]
102. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35-9. [PMID: 10877738]
103. Koblin BA, van Benthem BH, Buchbinder SP, Ren L, Vittinghoff E, Stevens CE, et al. Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995. Am J Epidemiol. 1999;150:1026-30. [PMID: 10568617]
104. Raboud JM, Rae S, Vella S, Harrigan PR, Bucciardini R, Fragola V, et al. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team. J Acquir Immune Defic Syndr. 1999;22:260-6. [PMID: 10770346]
105. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873-80. [PMID: 10513645]
106. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-7. [PMID: 9544767]
107. Staszewski S, Miller V, Sabin C, Berger A, Hill AM, Phillips AN. Rebound of HIV-1 viral load after suppression to very low levels [Letter]. AIDS. 1998;12:2360. [PMID: 9863886]
108. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses. 1999;15:1631-8. [PMID: 10606086]
109. Salzberger B, Rockstroh J, Wieland U, Franzen C, Schwenk A, Jütte A, et al. Clinical efficacy of protease inhibitor based antiretroviral combination therapy - a prospective cohort study. Eur J Med Res. 1999;4:449-55. [PMID: 10585299]
110. D'Amato RM, D'Aquila RT, Wein LM. Management of antiretroviral therapy for HIV infection: modelling when to change therapy. Antivir Ther. 1998;3:147-58. [PMID: 10682132]
111. Paredes R, Puig T, Arnó A, Negredo E, Balagué M, Bonjoch A, et al. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. J Acquir Immune Defic Syndr. 1999;22:132-8. [PMID: 10843526]
112. Butcher D, Greene J, Duong P, Markson L. Virologic response associated with a change in protease inhibitor therapy [Letter]. Arch Intern Med. 2000;160:394-5. [PMID: 10668845]
113. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-14. [PMID: 9543434]
114. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, et al. Virologic responses to a ritonavir - saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23-8. [PMID: 10202820]
115. Kaufmann GR, Duncombe C, Cunningham P, Beveridge A, Carr A, Sayer D, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS. 1998;12:1625-30. [PMID: 9764781]
116. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000;160:1123-32. [PMID: 10789605]
117. Guardiola JM, Domingo P, Vazquez G. Switching HIV-1 protease inhibitor therapy: which? When? And why? [Letter]. Arch Intern Med. 1999;159:194-5. [PMID: 9927104]
118. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351:543-9. [PMID: 9492772]
119. Casado JL, Perez-Elías MJ, Antela A, Sabido R, Martí-Belda P, Dronda F, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS. 1998;12:F131-5. [PMID: 9708403]
120. d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS. 1998;12:1631-7. [PMID: 9764782]
121. Roca B, Gómez CJ, Arnedo A. A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients. AIDS. 2000;14:157-61. [PMID: 10708286]
122. Roca B, Gómez CJ, Arnedo A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect. 1999;39:141-5. [PMID: 10609532]
123. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:290-4. [PMID: 10077179]
124. Sullivan AK, Nelson MR, Moyle GJ, Newell AM, Feher MD, Gazzard BG. Coronary artery disease occurring with protease inhibitor therapy. Int J STD AIDS. 1998;9:711-2. [PMID: 9863587]
125. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection [Editorial]. AIDS. 1999;13:2493-505. [PMID: 10630518]
126. Reijers MH, Weigel HM, Hart AA, Ten Kate RW, Mulder JW, Reiss P, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS. 2000;14:59-67. [PMID: 10714568]
127. Rhone SA, Hogg RS, Yip B, Sherlock C, Conway B, Schechter MT, et al. Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy? J Infect Dis. 1998;178:662-8. [PMID: 9728533]
128. Lauman EO. The Social Organization of Sexuality in America: Sexual Practices in the United States. Chicago: Univ Chicago Pr; 1994.
129. Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, Winkelstein W Jr. Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984-1989. J Acquir Immune Defic Syndr. 1993;6:303-12. [PMID: 8450406]
130. Keet IP, Albrecht van Lent N, Sandfort TG, Coutinho RA, van Griensven GJ. Orogenital sex and the transmission of HIV among homosexual men. AIDS. 1992;6:223-6. [PMID: 1558719]
131. Caceres CF, van Griensven GJ. Male homosexual transmission of HIV-1. AIDS. 1994;8:1051-61. [PMID: 7986400]
132. Deschamps MM, Pape JW, Hafner A, Johnson WD Jr. Heterosexual transmission of HIV in Haiti. Ann Intern Med. 1996;125:324-30. [PMID: 8678397]
133. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med. 1994;331:341-6. [PMID: 8028613]
134. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol. 1997;146:350-7. [PMID: 9270414]
135. Operskalski EA, Stram DO, Busch MP, Huang W, Harris M, Dietrich SL, et al. Role of viral load in heterosexual transmission of human
136. Musicco M, Lazzarin A, Nicolosi A, Gasparini M, Costigliola P, Arici C, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med. 1994;154:1971-6. [PMID: 8074601]
137. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-9. [PMID: 10738050]
138. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. Science. 1998;280:1889-94. [PMID: 9632382]
139. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280:1161-7. [PMID: 9777816]
140. DiClemente RJ, Wingood GM. A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. JAMA. 1995;274:1271-6. [PMID: 7563531]
141. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-31. [PMID: 11248160]
142. HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-23. [PMID: 11248159]
143. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42:1003-10. [PMID: 16511767]
144. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-9. [PMID: 10392984]
145. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-90. [PMID: 10647802]
146. Drugs for HIV infection. Med Lett Drugs Ther. 2000;42:1-6. [PMID: 10683666]
147. U.S. General Accounting Office, General Government Division. Funding implications of new combination therapies for Federal and State programs. Washington, DC: U.S. General Accounting Office General Government Division; 1998.
148. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Pharmacoeconomics. 1999;16:307-15. [PMID: 10558042]
149. Keiser P, Kvanli MB, Turner D, Reisch J, Smith JW, Nassar N, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:28-33. [PMID: 9928726]
150. Gable CB, Tierce JC, Simison D, Ward D, Motte K. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:413-20. [PMID: 8673552]
151. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102. [PMID: 8483408]
152. Tsevat J, Solzan JG, Kuntz KM, Ragland J, Currier JS, Sell RL, et al. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care. 1996;34:44-57. [PMID: 8551811]
153. Tsevat J, Sherman SN, McElwee JA, Mandell KL, Simbartl LA, Sonnenberg FA, et al. The will to live among HIV-infected patients. Ann Intern Med. 1999;131:194-8. [PMID: 10428736]
154. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care. 1995;33:AS173-82. [PMID: 7723445]
155. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475-81. [PMID: 12458977]
156. Honiden S, Nease RF, Sundaram V, Holodniy M, Owens DK. The effect of diagnosis with HIV infection on quality of life [Abstract]. Med Decis Making. 2002;22:560.
157. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Sanders GD, Taylor K, et al. Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Am J Public Health. 2007;97:2173-8. [PMID: 17971545]
158. Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged < or = 50 years compared with younger people in an urban observational cohort. Clin Infect Dis. 2003;36:212-8. [PMID: 12522755]
159. Executive Office of the President of the United States. Budget of the United States Government, Fiscal Year 2009: Section 10.1 - Gross Domestic Product and Deflators Used in the Historical Tables: 1940-2013. Accessed at www.gpoaccess.gov/usbudget/fy09/pdf/hist/pdf on 2 May 2008.
160. King JT Jr, Justice AC, Roberts MS, Chang CC, Fusco JS. Collaboration in HIV Outcomes Research-US Program Team. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making. 2003;23:9-20. [PMID: 12583451]
161. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357:762-74. [PMID: 17715410]
162. Stall R, Catania J. AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med. 1994;154:57-63. [PMID: 8267490]